Introduction: Granulysin is a cytotoxic granule protein of cytotoxic T-lymphocytes and natural killer cells. Gastric cancer patients of stage II and stage III were reported to have pre-operative serum granulysin, which is a good prognostic factor. Activated T lymphocytes produce a lot of granulysin in the cell. We hypothesized that activated T lymphocytes transfer therapy may increase in serum granulysin leveles of stage IV and relapsed patients.
Method: Between April 2002 and December 2007, the patients received a standard therapy with activated lymphocytes transfer therapy. Peripheral blood samples were taken from the patients. Serum granulysin concentrations were measured using a granulysin-specific ELISA kit.
Result: The average serum granulysin level for Stage IV (n=29) and relapsed patients (n=13) was 3.3 ng/mL. The gastric cancer patients were classified into two groups based on their concentration of serum granulysin level: high group (> or = 3.3 ng/mL); low group (< 3.3 ng/mL). There were no significant differences between these two groups in gender and age. The stage IV high group had a longer survival time than the stage IV low group. After 60 days from the activated T lymphocytes transfer therapy, the average pre-treatment serum granulysin had increased. However, there was no significant difference to note. It is noteworthy that serum granulysin is a novel parameter of patients cancer immunity.